Trastuzumab-RhodG

N/A

Report date: 2023/12/07 17:52:16

Base Information

Drug NameTrastuzumab-RhodG
Drug Alias NameHerceptin-RhodG
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsNeoplasm Metastasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A